TherapeuticsMD, Inc. (NYSEMKT:TXMD) that it will host its 2014 Investor Day on Monday, June 16, 2014, beginning at 11:30 a.m. TherapeuticsMD Inc. (NYSEMKT:TXMD) weekly performance is 4.38%. On last trading day company shares ended up $4.05. Analysts mean target price for the company is $9.75. TherapeuticsMD Inc. (NYSEMKT:TXMD) distance from 50-day simple moving average (SMA50) is -18.63%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is slated to be one of the presenters at the Jefferies 2014 Global Healthcare Conference on June 3rd, 2014. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares advanced 1.94% in last trading session and ended the day on $6.31. ARNA gross Margin is 93.70% and its return on assets is -8.10%.Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly performance is -9.86%.
Effective May 15, 2014, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) granted an exemption to BlackRock, Inc., together with its subsidiaries, affiliates and associates under the Company’s Section 382 Rights Agreement, dated as of October 31, 2013, between the Company and Computershare Trust Company, N.A., as rights agent following the determination by a designated committee of the Board of Directors of the Company that BlackRock and the various investment funds and accounts for which BlackRock acts, or may in the future act, as manager and/or investment advisor, are collectively an “Exempt Person” pursuant to Section 29 of the Rights Agreement. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved up 3.02% in last trading session and was closed at $6.49, while trading in range of $6.31 – $6.54. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is -4.84%.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) announced its latest earnings data on May 8, 2014. The company notched up $0.23 earnings per share in the last quarter. Orexigen Therapeutics has carried out ground breaking scientific innovations in the realm of drugs for treating obesity related disorders. Orexigen Therapeutics, Inc. (NASDAQ:OREX) ended the last trading day at $5.90. Company weekly volatility is calculated as 5.62% and price to cash ratio as 4.42.Orexigen Therapeutics, Inc. (NASDAQ:OREX) showed a positive weekly performance of 7.27%.
Eisai Co., Ltd. (ADR) (OTCMKTS:ESALY) announced that its U.K. subsidiary Eisai Europe Limited has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on the indication expansion of Halaven(R) (generic name: eribulin mesylate, “eribulin”) to contribute to earlier-line treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments. On last trading day company shares ended up $40.92.
Leave a Reply